Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

A Dose Block-randomized, Double-blinded, Placebo-controlled, Single-dose, Dose-escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of HL-032 in Healthy Male Volunteers

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of HL-032 after oral administration in healthy male volunteers.

Inclusion Criteria:

• Healthy male subjects
• Age(yr)between 19 and 50
• Signed written informed consent

Exclusion Criteria:

• Known hypersensitivity to Octreotide or hGH(human growth hormone)
• History of Cardiovascular, Respiratory, Renal/Genitourinary, Gastrointestinal, Neurological/Psychic, cancer
• Alcoholic, smokers or drug abusers
• Other conditions which in the opinion of the investigator preclude enrollment into the study